Veloxis Pharmaceuticals A/S Envarsus® Granted Orphan Drug Status By FDA For Kidney Transplant Rejection Prophylaxis

Veloxis Pharmaceuticals A/S (OMX: VELO), today announced that Envarsus® was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients receiving allogenic kidney transplants. The designation is to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases. Envarsus® is Veloxis’ once-daily formulation of tacrolimus employing the company’s proprietary MeltDose® technology.

Help employers find you! Check out all the jobs and post your resume.